Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Company profile
Ticker
DRNA
Exchange
Website
CEO
Douglas Fambrough
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dicerna Security Corporation • Dicerna EU Limited • Dicerna Ireland Limited • Dicerna Germany GmbH ...
DRNA stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
10 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
EFFECT
Notice of effectiveness
3 Jan 22
POSASR
Automatic shelf registration (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
POS AM
Prospectus update (post-effective amendment)
28 Dec 21
Transcripts
DRNA
Earnings call transcript
2021 Q3
9 Nov 21
DRNA
Earnings call transcript
2021 Q2
9 Aug 21
DRNA
Earnings call transcript
2021 Q1
8 May 21
DRNA
Earnings call transcript
2020 Q4
26 Feb 21
DRNA
Earnings call transcript
2020 Q3
7 Nov 20
DRNA
Earnings call transcript
2020 Q2
10 Aug 20
DRNA
Earnings call transcript
2020 Q1
11 May 20
DRNA
Earnings call transcript
2019 Q4
28 Feb 20
DRNA
Earnings call transcript
2019 Q3
10 Nov 19
DRNA
Earnings call transcript
2019 Q2
8 Aug 19
Latest ownership filings
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 171.37 mm | 171.37 mm | 171.37 mm | 171.37 mm | 171.37 mm | 171.37 mm |
Cash burn (monthly) | 18.48 mm | 3.27 mm | 6.76 mm | 10.18 mm | 21.26 mm | (no burn) |
Cash used (since last report) | 570.34 mm | 100.97 mm | 208.50 mm | 314.09 mm | 656.02 mm | n/a |
Cash remaining | -398.97 mm | 70.40 mm | -37.12 mm | -142.72 mm | -484.65 mm | n/a |
Runway (months of cash) | -21.6 | 21.5 | -5.5 | -14.0 | -22.8 | n/a |
Institutional ownership, Q1 2023
3.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 66.93 mm |
Total shares | 2.79 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Fund | 2.79 mm | $66.93 mm |